Wafer-scale, fully automated solid-state nanopore fabrication for biomolecular sensing

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2022
  • Known Financial Commitments (USD)

    $180,298.5
  • Funder

    ERC
  • Principal Investigator

    Amit Meller
  • Research Location

    Israel
  • Lead Research Institution

    Technion - Israel Institute of Technology
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Solid-state nanopores (ssNPs) are an emerging class of single-molecule devices, which have proven useful in a broad range of applications, from sensing COVID-19 RNAs to proteins biomarkers. To date, ssNP fabrication costs, throughput and instrumentation have remained the bottlenecks towards broad adoption of ssNP sensing in biomedical research labs and in industry. To address this need, we will apply our optical method for the creation of nanoscale apertures in thin films. OptiPore aims are to design, construct, test, disseminate and commercialize an autonomous high-throughput laser-based drilling apparatus, drastically reducing ssNP current costs and thereby opening vast opportunities for accessible ssNP sensing applications. OptiPore is both innovative and distinctive in aiming to reduce to practice an affordable technology for high-throughput and low-cost NP fabrication. The laser-based NP drilling technology we have developed is an emerging technique that is highly distinctive from other ssNP fabrication methods available. OptiPore will remove a major technical roadblock in the commercialization path of ssNPs in biomedical applications, hence addressing an economical and societal need. Commercialization of our technology will proceed in three parallel paths aiming to bring affordable, high quality, ssNPs biosensors to the broadest possible industrial usages.